Syndax Pharmaceuticals Inc. (1T3)
XFRA 
Summary
1T3 Chart
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth
Syndax Pharmaceuticals (SNDX) posted strong Q3 results, driven by robust Revuforj and Niktimvo sales, despite a slight revenue miss. SNDX's commercial ramp is accelerating, with Revuforj prescriptions up 25% and management confident cash reserves will fund operations to profitability. 2026 revenue projections for SNDX range from $245M to $512M, depending on growth scenarios, but risks include reimbursement and competitive shifts.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript
Syndax Pharmaceuticals, Inc. ( SNDX ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Okay. Well, thanks for joining.
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its addressable market, reinforcing first-mover advantage and supporting $1B+ peak sales potential. Niktimvo's robust uptake and Incyte partnership will aid the march to profitability, while also providing significant downside cushion.
Syndax Pharmaceuticals Inc. (1T3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Syndax Pharmaceuticals Inc. ever had a stock split?
Syndax Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael A. Metzger CEO | XFRA Exchange | US87164F1057 ISIN |
| US Country | 270 Employees | - Last Dividend | - Last Split | 3 Mar 2016 IPO Date |
Overview
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical organization focused on the discovery and development of novel treatments for cancer. Established in 2005, the company is driven by a commitment to provide innovative therapies that address unmet medical needs in the oncology space. With its headquarters in Waltham, Massachusetts, Syndax Pharmaceuticals has positioned itself as a leader in the fight against cancer, leveraging cutting-edge science and research to develop transformative medicines. The firm’s dedication to advancing cancer treatment is evidenced by its robust pipeline of product candidates and partnerships aimed at enhancing the development and commercialization of its potential treatments. Through strategic collaborations and a deep understanding of cancer biology, Syndax is working to bring new hope to patients suffering from this devastating disease.
Products and Services
- Revumenib
Revumenib stands out as Syndax Pharmaceuticals' leading product candidate, configured as a powerful and selective small molecule inhibitor targeting the menin-MLL binding interaction. It is primarily being developed for the treatment of KMT2A rearranged acute leukemias and solid tumors. Revumenib's mechanism of action disrupts critical protein interactions responsible for the growth of certain cancer cells, offering a novel approach to treating these malignancies.
- SNDX-6352/Axatilimab
Another pivotal product in Syndax's lineup is SNDX-6352, also known as axatilimab. This therapeutic is a monoclonal antibody designed to inhibit the colony stimulating factor 1 receptor (CSF-1R). Its primary indications are for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF), two conditions with significant unmet medical needs. By blocking CSF-1R, axatilimab may help modulate the immune response and alleviate the symptoms of these serious diseases.
- Entinostat
Beyond revumenib and axatilimab, Syndax is also advancing Entinostat, another flagship investigational compound. While specific details regarding its mechanism and targeted indications were not provided in the overview, Entinostat represents a crucial part of the company's diversified portfolio in oncology. Syndax has secured a licensing and development agreement with Eddingpharm International Company Limited, aimed at bolstering the commercialization prospects of Entinostat, indicating its potential significance in cancer treatment regimens.
Contact Information
